4.22
price up icon50.71%   1.42
after-market Handel nachbörslich: 3.92 -0.30 -7.11%
loading
Schlusskurs vom Vortag:
$2.80
Offen:
$2.97
24-Stunden-Volumen:
6.28M
Relative Volume:
15.74
Marktkapitalisierung:
$4.90M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-36.46M
KGV:
-1.7583
EPS:
-2.4
Netto-Cashflow:
$-30.20M
1W Leistung:
+177.63%
1M Leistung:
+168.79%
6M Leistung:
+54.01%
1J Leistung:
-76.81%
1-Tages-Spanne:
Value
$2.732
$4.79
1-Wochen-Bereich:
Value
$1.3137
$4.79
52-Wochen-Spanne:
Value
$1.3137
$18.20

Alaunos Therapeutics Inc Stock (TCRT) Company Profile

Name
Firmenname
Alaunos Therapeutics Inc
Name
Telefon
(346) 355-4099
Name
Adresse
2617 BISSONNET ST, HOUSTON
Name
Mitarbeiter
0
Name
Twitter
Name
Nächster Verdiensttermin
2024-12-12
Name
Neueste SEC-Einreichungen
Name
TCRT's Discussions on Twitter

Vergleichen Sie TCRT mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
TCRT
Alaunos Therapeutics Inc
4.22 4.90M 0 -36.46M -30.20M -2.40
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.01 125.55B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.64 67.78B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
590.06 36.24B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
262.16 33.99B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
264.32 28.77B 3.81B -644.79M -669.77M -6.24

Alaunos Therapeutics Inc Stock (TCRT) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2022-10-04 Fortgesetzt Wells Fargo Overweight

Alaunos Therapeutics Inc Aktie (TCRT) Neueste Nachrichten

pulisher
Mar 27, 2025

Alaunos Therapeutics (NASDAQ:TCRT) Shares Down 6.5% – Here’s What Happened - Defense World

Mar 27, 2025
pulisher
Jan 29, 2025

Lantheus acquires radiopharma CDMO Evergreen for up to $1bn - Pharmaceutical Technology

Jan 29, 2025
pulisher
Jan 15, 2025

Alaunos Therapeutics (NASDAQ:TCRT) Stock Price Up 4% – Should You Buy? - Defense World

Jan 15, 2025
pulisher
Jan 10, 2025

Light Horse emerges with $62m and Novartis partnership worth up to $1bn - Pharmaceutical Technology

Jan 10, 2025
pulisher
Dec 24, 2024

Alaunos Therapeutics (NASDAQ:TCRT) Stock Price Down 0.5% – Time to Sell? - Defense World

Dec 24, 2024
pulisher
Dec 13, 2024

TCRT stock touches 52-week low at $1.92 amid market challenges - Investing.com

Dec 13, 2024
pulisher
Nov 22, 2024

Novartis acquires Kate Therapeutics to advance gene therapies - Pharmaceutical Technology

Nov 22, 2024
pulisher
Nov 15, 2024

Alaunos Therapeutics Inc (TCRT) Quarterly 10-Q Report - Quartzy

Nov 15, 2024
pulisher
Nov 14, 2024

Ziopharm: Q3 Earnings Snapshot - The Washington Post

Nov 14, 2024
pulisher
Nov 08, 2024

TCRT Stock Touches 52-Week Low at $1.96 Amid Market Challenges - Investing.com Nigeria

Nov 08, 2024
pulisher
Oct 28, 2024

TCRT stock touches 52-week low at $2.06 amid market challenges - Investing.com

Oct 28, 2024
pulisher
Oct 13, 2024

Intracranial Therapeutic Market Rewriting its Growth Cycle |Novartis AG, BioMarin, CORESTEM Inc., Alaunos Therapeutics, – IndiaPolitics.com - IndiaPolitics.com

Oct 13, 2024
pulisher
Oct 11, 2024

After axing its sole clinical prospect last year, Alaunos cuts ties with Precigen - Fierce Biotech

Oct 11, 2024
pulisher
Oct 11, 2024

Alaunos Therapeutics ends key agreement and updates on financial condition By Investing.com - Investing.com Australia

Oct 11, 2024
pulisher
Oct 11, 2024

Alaunos Therapeutics Ends Licensing Deal, Reassesses Strategy - Yahoo Finance

Oct 11, 2024
pulisher
Oct 11, 2024

Precigen reclaims rights after terminating license agreement - Investing.com India

Oct 11, 2024
pulisher
Oct 10, 2024

Precigen Terminates License Agreement With Alaunos Therapeutics - MarketWatch

Oct 10, 2024
pulisher
Oct 10, 2024

Alaunos Therapeutics ends key agreement and updates on financial condition - Investing.com

Oct 10, 2024
pulisher
Oct 01, 2024

Genentech buys Regor’s CDK inhibitors in $850m deal - Clinical Trials Arena

Oct 01, 2024
pulisher
Sep 26, 2024

AskBio and Belief BioMed partner to advance gene therapies - Pharmaceutical Technology

Sep 26, 2024
pulisher
Sep 18, 2024

Gene Switch / Molecular Switch Market Set to Reach USD 1.44 Billion by 2031 with 9.9% CAGR - WhaTech

Sep 18, 2024
pulisher
Sep 11, 2024

Gilead and Genesis partner to create novel therapies using AI - Pharmaceutical Technology

Sep 11, 2024
pulisher
Aug 28, 2024

Navigator gains $100m in Series A funding for antibody therapeutics - Pharmaceutical Technology

Aug 28, 2024
pulisher
Aug 23, 2024

VION Biosciences acquires Echelon Biosciences - Pharmaceutical Technology

Aug 23, 2024
pulisher
Aug 14, 2024

Eli Lilly inaugurates R&D facility in Boston, US - Pharmaceutical Technology

Aug 14, 2024
pulisher
Aug 07, 2024

Genentech and Sangamo to develop neurodegenerative disease therapies - Pharmaceutical Technology

Aug 07, 2024
pulisher
Jul 16, 2024

Alaunos Therapeutics announces 1-for-10 reverse stock split - Investing.com

Jul 16, 2024
pulisher
Jul 11, 2024

XyloCor taps SmartWise’s infusion device for gene therapy administration - Clinical Trials Arena

Jul 11, 2024
pulisher
May 29, 2024

Turn Bio and HanAll to develop therapies for age-related conditions - Pharmaceutical Technology

May 29, 2024
pulisher
Mar 27, 2024

Avenzo Therapeutics secures $150m to bolster oncology pipeline - Pharmaceutical Technology

Mar 27, 2024
pulisher
Mar 25, 2024

Gilead concludes acquisition of CymaBay Therapeutics for $4.3bn - Pharmaceutical Technology

Mar 25, 2024
pulisher
Feb 01, 2024

Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session - Markets Insider

Feb 01, 2024
pulisher
Jan 30, 2024

Alaunos Therapeutics Announces 1-for-15 Reverse Stock Split - TipRanks

Jan 30, 2024
pulisher
Jan 29, 2024

TScan Therapeutics Appoints Jason A. Amello as Chief Financial Officer - citybiz

Jan 29, 2024
pulisher
Jan 25, 2024

Kyowa Kirin acquires Orchard Therapeutics for $477.6m - Pharmaceutical Technology

Jan 25, 2024
pulisher
Jan 24, 2024

NAYA buys gene therapy company Florida Biotech for $20m - Clinical Trials Arena

Jan 24, 2024
pulisher
Jan 23, 2024

Genentech signs nanoparticle deal worth up to $644m with GenEdit - Pharmaceutical Technology

Jan 23, 2024
pulisher
Jan 08, 2024

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - InvestorPlace

Jan 08, 2024
pulisher
Jan 05, 2024

Avistone raises $140m to support drug research and development - Pharmaceutical Technology

Jan 05, 2024
pulisher
Jan 04, 2024

BridGene and Galapagos partner for oncology drugs discovery - Pharmaceutical Technology

Jan 04, 2024
pulisher
Jan 03, 2024

Novartis allies with Voyager to develop gene therapies in $1.3bn deal - Pharmaceutical Technology

Jan 03, 2024
pulisher
Dec 18, 2023

Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today? - MSN

Dec 18, 2023
pulisher
Dec 18, 2023

Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day Session - Markets Insider

Dec 18, 2023
pulisher
Nov 23, 2023

Syncona to buy biotechnology company Freeline Therapeutics - Pharmaceutical Technology

Nov 23, 2023
pulisher
Nov 14, 2023

Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives - Yahoo Finance

Nov 14, 2023
pulisher
Nov 09, 2023

Ascidian Therapeutics raises $40m to advance drug development - Pharmaceutical Technology

Nov 09, 2023
pulisher
Nov 01, 2023

AstraZeneca and Cellectis partner to advance cell and gene therapies - Pharmaceutical Technology

Nov 01, 2023
pulisher
Oct 26, 2023

How gene therapies can transform sickle cell disease treatment - Pharmaceutical Technology

Oct 26, 2023
pulisher
Aug 16, 2023

Alaunos (TCRT) to Wind Down Sole Clinical Study, Stock Dips 65% - Nasdaq

Aug 16, 2023
pulisher
Aug 15, 2023

Houston biotech winds down sole clinical-stage trial, cuts 60% of staff - Fierce Biotech

Aug 15, 2023
pulisher
Jul 18, 2023

Neoleukin to merge with Neurogene for $200m in cash reserves - Pharmaceutical Technology

Jul 18, 2023

Finanzdaten der Alaunos Therapeutics Inc-Aktie (TCRT)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
Kapitalisierung:     |  Volumen (24h):